P668: acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ascend results at ~4 years of follow-upP. Ghia, A. Pluta, M. Wach,D. Lysak,M. Simkovic,I. Kriachok,A. Illes,J. de la Serna, S. Dolan, P. Campbell, G. Musuraca, A. Jacob, E. Avery,J. H. Lee, G. Usenko,M. H. Wang, T. Yu,W. JurczakHemaSphere（2022）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
